CN101417067B - 一种具有抗肿瘤作用的药物组合物 - Google Patents
一种具有抗肿瘤作用的药物组合物 Download PDFInfo
- Publication number
- CN101417067B CN101417067B CN200710163373A CN200710163373A CN101417067B CN 101417067 B CN101417067 B CN 101417067B CN 200710163373 A CN200710163373 A CN 200710163373A CN 200710163373 A CN200710163373 A CN 200710163373A CN 101417067 B CN101417067 B CN 101417067B
- Authority
- CN
- China
- Prior art keywords
- artificial
- mice
- pharmaceutical composition
- olibanum
- myrrha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 230000000259 anti-tumor effect Effects 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 239000004863 Frankincense Substances 0.000 claims description 33
- 239000009636 Huang Qi Substances 0.000 claims description 32
- 241001057584 Myrrha Species 0.000 claims description 31
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 29
- 241000180649 Panax notoginseng Species 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 239000002398 materia medica Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000972155 Moschus Species 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 59
- 241000699670 Mus sp. Species 0.000 abstract description 53
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract description 28
- 229960004397 cyclophosphamide Drugs 0.000 abstract description 24
- 210000002784 stomach Anatomy 0.000 abstract description 17
- 206010003445 Ascites Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 abstract description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract description 6
- 239000003228 hemolysin Substances 0.000 abstract description 6
- 230000036737 immune function Effects 0.000 abstract description 6
- 230000000242 pagocytic effect Effects 0.000 abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 235000003717 Boswellia sacra Nutrition 0.000 abstract description 2
- 240000007311 Commiphora myrrha Species 0.000 abstract description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 2
- 239000000890 drug combination Substances 0.000 abstract 2
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 210000000683 abdominal cavity Anatomy 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000013017 Child Nutrition disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000009874 shenqi Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量(g生药/kg) | 动物数(只) | 瘤重(g) | 抑瘤率(%) |
模型组大剂量组中剂量组小剂量组环磷酰胺对照组 | 等体积CMC3.151.580.7920mg/kg | 1515151515 | 1.91±0.5451.28±0.597*1.47±0.271*1.71±0.4460.69±0.213** | -32.9823.010.563.9 |
组别 | 剂量(g生药/kg) | 动物数(只) | 瘤重(g) | 抑瘤率(%) |
模型组大剂量组中剂量组小剂量组环磷酰胺组 | 同体积CMC3.151.580.7920mg/kg | 1010101010 | 1.163±0.2030.777±0.201**0.893±0.301*1.045±0.2490.799±0.132** | -33.223.210.280.3 |
组别 | 剂量(g生药/kg) | 动物数(只) | 胸腺指数(mg/g) | 脾指数(mg/g) |
空白组模型组大剂量组中剂量组小剂量组环磷酰胺组 | 同体积CMC同体积CMC3.151.580.7920mg/kg | 121212121212 | 2.44±0.361.69±0.28△△1.88±0.31.81±0.411.77±0.341.03±0.17** | 4.85±0.859.06±3.34△△8.15±2.6148.59±2.198.43±2.886.52±2.18** |
组别 | 动物数(只) | 剂量(g生药/kg) | 廓清指数(K) | 校正廓清活性(a) |
空白组模型组大剂量组中剂量组小剂量组参芪胶囊组 | 131313131313 | 同体积CMC同体积CMC3.151.580.791.8 | 0.0912±0.0250.0322±0.012△△0.0754±0.0 39*0.0494±0.021*0.0461±0.0190.0714±0.02* | 6.413±0.5454.731±0.574△△5.750±1.2774.900±0.4974.782±0.7525.713±1.431 |
组别 | 动物数(只) | 剂量(g生药/kg) | OD值 |
空白组模型组大剂量组中剂量组小剂量组参芪胶囊组 | 131213131313 | 同体积0.5%CMC同体积0.5%CMC3.151.580.791.8 | 0.0756±0.0220.0372±0.014△△0.0559±0.018**0.0568±0.022*0.0468±0.012*0.0559±0.013** |
组别 | 剂量(g生药/kg) | 鼠数(只) | 存活时间(d) | 延长率(%) |
模型组大剂量组中剂量组小剂量组环磷酰胺组环磷酰胺组 | 等体积0.5%CMC3.151.580.795mg/kg20mg/kg | 151515151515 | 19.5±2.426.0±278*23.4±2.721.6±2.422.5±2.434.4±3.4** | -33.220.1710.5915.3676.1 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710163373A CN101417067B (zh) | 2007-10-23 | 2007-10-23 | 一种具有抗肿瘤作用的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710163373A CN101417067B (zh) | 2007-10-23 | 2007-10-23 | 一种具有抗肿瘤作用的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101417067A CN101417067A (zh) | 2009-04-29 |
CN101417067B true CN101417067B (zh) | 2012-10-03 |
Family
ID=40628193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710163373A Active CN101417067B (zh) | 2007-10-23 | 2007-10-23 | 一种具有抗肿瘤作用的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101417067B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721340B (zh) * | 2009-10-23 | 2012-02-15 | 无限极(中国)有限公司 | 一种用于延缓肌肤衰老的化妆品组合物 |
CN101849981B (zh) * | 2010-06-22 | 2011-11-23 | 南京中医药大学 | 一种具有抗妇科肿瘤作用的没药有效部位及其制备方法和其应用 |
CN104013920A (zh) * | 2014-06-26 | 2014-09-03 | 王芬 | 一种治疗胃癌的中药组合物 |
CN108815349A (zh) * | 2018-08-31 | 2018-11-16 | 刘正奇 | 一种抗癌、抗肿瘤的中药配方及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130088A (zh) * | 1995-12-28 | 1996-09-04 | 安徽药都药业有限公司 | 一种纯中药抗癌药物 |
-
2007
- 2007-10-23 CN CN200710163373A patent/CN101417067B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130088A (zh) * | 1995-12-28 | 1996-09-04 | 安徽药都药业有限公司 | 一种纯中药抗癌药物 |
Non-Patent Citations (1)
Title |
---|
郁仁存.关于中医药治疗恶性肿瘤的讨论.《中国医刊》.-001,(第10期),7-10. * |
Also Published As
Publication number | Publication date |
---|---|
CN101417067A (zh) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102068707B (zh) | 一种b超使用的中药助影剂及其制备方法 | |
CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN102078569B (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN101716318A (zh) | 一种治疗消化系统肿瘤的中药制剂 | |
CN101417067B (zh) | 一种具有抗肿瘤作用的药物组合物 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN101518594B (zh) | 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 | |
CN101342357B (zh) | 治疗乳腺增生及防治乳腺癌的中药组合物 | |
CN102805843A (zh) | 一种治疗胃痛的药物及其制备方法 | |
CN101564464B (zh) | 一种调节肿瘤患者机体免疫力的中药药物 | |
CN102949571B (zh) | 一种治疗慢性骨髓炎的药物 | |
CN105232764A (zh) | 一种治疗胃绞痛、胆囊绞痛、胆汁倒流引起疼痛的藏药复方藏药制剂 | |
CN100509041C (zh) | 清胃排毒丸 | |
CN102846794B (zh) | 治疗癌症的药物组合物及其制备方法 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
CN105031302A (zh) | 一种辅助治疗艾滋病免疫功能重建不全的中药组合物 | |
CN103028028B (zh) | 一种治疗原发性肝癌的中药 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN103610991B (zh) | 用于治疗猪胃溃疡的药物及其制备方法 | |
CN116019891B (zh) | 一种治疗耳鸣耳聋的中药膏方及其制备方法 | |
CN101530589B (zh) | 一种治疗癌症的中药制剂 | |
CN105456951A (zh) | 一种治疗乳房纤维腺瘤的中药制剂及其制备方法 | |
CN104645243A (zh) | 一种治疗脑膜瘤的中药组合物及其制备方法 | |
CN111729053A (zh) | 疏肝和胃的中药组合物、胃特安丸以及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING KOWLOON PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LEI HAIMIN Effective date: 20130603 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100102 CHAOYANG, BEIJING TO: 102100 YANQING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130603 Address after: 102100 Yanqing economic and Technological Development Zone, Yanqing, Beijing Patentee after: Beijing Kowloon Pharmaceutical Co., Ltd. Address before: 100102 Department of traditional Chinese medicine, School of traditional Chinese medicine, Beijing University of Chinese Medicine, 6 South Central Road, Wangjing, Beijing, Chaoyang District Patentee before: Lei Haimin |